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Production of the human immunodeficiency virus type 1 (HIV-1) Gag-Pol precursor protein results from a
21 ribosomal frameshifting event. In infected cells, this generates Gag and Gag-Pol in a ratio that is estimated
to be 20:1, a ratio that is conserved among retroviruses. To examine the impact of this ratio on HIV-1 repli-
cation and viral assembly, we altered the Gag/Gag-Pol ratio in virus-producing cells by cotransfecting HIV-1
proviral DNA with an HIV-1 Gag-Pol expression vector. Two versions of the Gag-Pol expression vector were
used; one contains an active protease [PR(1)], and the other contains an inactive protease [PR(2)]. In an at-
tempt to produce viral particles with Gag/Gag-Pol ratios ranging from 20:21 to 20:1 (wild type), 293T cells were
cotransfected with various ratios of wild-type proviral DNA and proviral DNA from either Gag-Pol expression
vector. Viral particles derived from cells with altered Gag/Gag-Pol ratios via overexpression of PR(2) Gag-Pol
showed a ratio-dependent defect in their virion protein profiles. However, the defects in virion infectivity were
independent of the nature of the Gag-Pol expression vector, i.e., PR(1) or PR(2). Based on equivalent input
of reverse transcriptase activity, we estimated that HIV-1 infectivity was reduced 250- to 1,000-fold when the
Gag/Gag-Pol ratio in the virion-producing cells was altered from 20:1 to 20:21. Although virion RNA packaging
was not affected by altering Gag/Gag-Pol ratios, changing the ratio from 20:1 to 20:21 progressively reduced
virion RNA dimer stability. The impact of the Gag/Gag-Pol ratio on virion RNA dimerization was amplified
when the Gag-Pol PR(2) expression vector was expressed in virion-producing cells. Virions produced from
cells expressing Gag and Gag-Pol PR(2) in a 20:21 ratio contained mainly monomeric RNA. Our observations
provide the first direct evidence that, in addition to proteolytic processing, the ratio of Gag/Gag-Pol proteins
is also important for RNA dimerization and that stable RNA dimers are not required for encapsidation of
genomic RNA in HIV-1.
The genome of the human immunodeficiency virus type 1
(HIV-1), like that of other retroviruses, contains three major
structural genes, gag, pol, and env. The Gag and Pol proteins
are encoded by overlapping open reading frames. Gag has its
own initiation and termination codons, while the synthesis of
the HIV-1 Gag-Pol precursor results from a 21 frameshifting
event that occurs at a frequency of 5 to 10% during translation
of the unspliced Gag or Gag-Pol mRNA (18). Other retrovi-
ruses also use similar frameshifting mechanisms (17, 19, 20) or
a readthrough suppression mechanism (8–10) to regulate the
expression of Gag-Pol proteins. Thus, intracellular Gag/Gag-
Pol ratios of around 20:1 are found during the replication of all
retroviruses. The HIV frameshift site (a heptanucleotide AU-
rich sequence) is found at the 39 end of the nucleocapsid (NC)
coding sequence. This site and a stem structure immediately
downstream stall the ribosome during the synthesis of Gag,
allowing the ribosome to slip back 1 nucleotide to enable the
infrequent (5%) synthesis of the Gag-Pol fusion protein (18).
Multimerization of the Gag protein gives rise to viral particles,
while expression of polymerase as a Gag-Pol precursor protein
ensures that viral enzymes are incorporated into viral particles
during viral assembly (for a review, see reference 27). During
and after release of virions from cells, the Gag precursor pro-
tein is cleaved by viral protease (PR) into mature proteins:
matrix, capsid (CA), NC, p6, and two spacer peptides, p2 and
p1. Gag-Pol fusion is cleaved to yield matrix, CA, p2, and NC,
as well as transframe protein, PR, reverse transcriptase (RT),
and integrase (IN).
The synthesis of Gag precursor protein alone has been re-
ported to be sufficient for the assembly and release of virus-like
particles (for a review, see reference 45). Incorporation of
Gag-Pol or its mature products into virions is required for
infectivity, as they mediate the synthesis and integration of
viral cDNA in infected cells (46). In addition, cleavage of the
precursor proteins by PR is required for morphological matu-
ration of the virion core (15, 23, 24). Viral genomic RNA is
also packaged into virions during assembly, driven by the ge-
nomic RNA packaging sequence (C) found near the 59 end of
the genome (for a review, see references 3 and 42).
Like other retroviruses, HIV-1 has a dimeric RNA genome.
In vitro dimerization analysis of HIV-1 viral RNA has mapped
a 50- to 60-nucleotide sequence, termed the dimer initiation
sequence, that is important for the formation of the dimeric
RNA complex (26, 31, 40). Mutations in the dimer initiation
sequence hinder genomic RNA dimerization and virion RNA
packaging and result in the production of noninfectious viral
particles. It is thought that RNA dimerization is a prerequisite
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for RNA packaging in HIV-1 (2, 6), and virion packaging of
genomic RNA and RNA dimerization are also linked in other
retroviruses (5, 38, 44). RNA dimers from PR-defective HIV-1
virions are less heat stable than dimers from wild-type mature
HIV-1 (11). Similar observations about Moloney murine leu-
kemia virus have also been reported (12).
Although it is clear that expression of the Gag-Pol precursor
alone is insufficient for production of infectious retroviral par-
ticles (7, 32), the influence of the Gag/Gag-Pol ratio (20:1) on
the viral replication cycle and RNA dimerization is unknown.
Our data show that the Gag/Gag-Pol ratio in virion-producing
cells is important for the generation of infectious viral particles
and the stability of the virion RNA dimer.
MATERIALS AND METHODS
Construction of DNA plasmids. The full-length wild-type HIV-1 plasmid,
referred to as HxB2-BH10, has been described previously (43). The DRev plas-
mid differs from HxB2-BH10 by the absence of the full second half of exon 2 of
the rev sequence, which was removed to inactivate Rev function. The Rev
deletion was achieved by BamHI and XhoI endonuclease digestion, followed by
ligation in the presence of a double-stranded DNA adapter which is comple-
mentary to both BamHI and XhoI. The GP PR(1) plasmid was constructed
using stitch PCR mutagenesis as previously described (30) (Fig. 1). Briefly, GP
sense f1 primer 59ggcaaagaagggcacacagcc39 and antisense f1 primer 59cccTGA
GGAAGttagcctgtctctcagtac39 were used to amplify a 130-bp GP f1 fragment. GP
sense f2 primer 59ggctaaCTTCCTCAgggaagatctggccttcc39 and GP antisense f2
primer 59gttgacaggtgtaggtcctac39 were used to amplify a 400-bp GP f2 fragment.
The GP f1 and GP f2 fragments were joined by PCR extension. The resulting
PCR-amplified fragment was cloned into the HxB2-BH10 proviral DNA via
restriction sites ApaI and BclI. The GP f1 antisense and GP f2 sense primers
contain mutations that eliminate the five-T heptanucleotide stretch which is
responsible for the 21 ribosomal frameshifting during the translation of Gag
(18). This GP mutation allows continuous expression of Gag-Pol and bypasses
the Gag termination codon. The GP PR(2) plasmid was constructed in the same
fashion as GP PR(1), with the exception that a PR-defective full-length HIV-1
plasmid PR(2) (15) was used as the DNA template for GP PR(2) PCR mu-
tagenesis (15). PR(2) was used for the production of PR-defective immature
HIV-1 virions as a control.
Cotransfection and virus production. The production of HIV-1 viral particles
from cells with an altered Gag/Gag-Pol ratio was achieved by cotransfecting 10
mg of proviral DNA (either HxB2-BH10 or DRev) with one of the two Gag-Pol
expression vectors [GP PR(1) or GP PR(2)] using the indicated amounts of
proviral DNA (see Table 1). Appropriate amounts of a long terminal repeat
promotor-driven luciferase reporter plasmid were used to normalize the level of
DNA used in cotransfection. HxB2-BH10 or DRev was responsible for the 20:1
Gag/Gag-Pol expression ratio in the virus-producing cells, while GP PR(1) and
GP PR(2) supplemented the excess of Gag-Pol protein expression in these cells.
Supplementation of 10, 5, 2.5, and 1.25 mg of the Gag-Pol expression vectors
altered the Gag/Gag-Pol ratio in the HIV-1-producing cells from 20:1 to 20:21,
20:11, 20:6, and 20:3.5, respectively. HxB2-BH10 and the Gag-Pol expression
vector GP PR(1) or GP PR(2) were used in cotransfections to produce viral
particles for virus infectivity analysis and viral protein profiles within both cel-
lular and virion lysates. DRev and a Gag-Pol expression vector, GP PR(1) or GP
PR(2), were used in cotransfection experiments to produce mutant viral parti-
cles for virion RNA packaging and dimerization analysis. A green fluorescent
protein (EGFP; Clontech) reporter plasmid (2 mg) was added to the DNA
mixture to determine transfection efficiency.
293T cells (1.2 3 106 cells per plate) were plated onto 10-cm-diameter plates
(Nunc) and maintained for 24 h in 7 ml of Dulbecco’s modified Eagle medium
(GIBCO) containing 10% fetal bovine serum (P. A. Biological Co.), 100 U of
penicillin per ml, and 100 mg of streptomycin per ml. DNA mixtures were
introduced into 293T cells using a previously described calcium phosphate trans-
fection method (29). Cells were washed twice with phosphate-buffered saline
12 h posttransfection and maintained in fresh Dulbecco’s modified Eagle me-
dium. Supernatants were collected 36 h posttransfection and centrifuged for 30
min at 3,000 rpm at 4°C (Beckman) to remove cellular debris. The clarified
supernatants were either frozen at 270°C or used immediately for further anal-
ysis. Cells were washed twice with either phosphate-buffered saline or 13 Tris-
buffered saline (TBS buffer, i.e., 50 mM Tris [pH 7.4], 150 mM NaCl), followed
by protein extraction using lysis buffer containing 13 TBS, Nonidet P-40 at 10
ml/ml, 20 mM phenylmethylsulfonyl fluoride, 1 mM pepstatin, and 1 mM leupep-
tin. Cell lysates were collected and stored at 220°C for later use.
Assessment of virus replication kinetics. (i) Preparation of viral particles for
infectivity assay. Supernatants obtained from cotransfection of 293T cells were
filtered immediately after centrifugation using 0.2-mm-pore-size filters (Schlei-
cher & Schu¨ll). Small volumes of samples were stored at 270°C. Samples were
thawed immediately before use for RT and infectivity assays.
(ii) RT activity of clarified virus supernatants. To determine the RT levels of
each virus, 10 ml of supernatant from each sample was mixed with 10 ml of
Nonidet P-40. Samples were incubated for 30 min at room temperature for
inactivation of the virus, and the RT activity of the viruses in the supernatant was
measured using an RT microassay as previously described (13).
(iii) p24 assay. p24 levels in culture supernatant were quantified via a com-
mercially available p24 antigen detection kit (Abbott Laboratories) used in
accordance with the manufacturer’s instructions.
(iv) Infectivity assay. Briefly, peripheral blood mononuclear cells (PBMCs)
were isolated from buffy pack (supplied by the Red Cross Blood Bank, Mel-
bourne, Victoria, Australia) as described previously (4). PBMCs were then stim-
ulated with phytohemagglutinin (10 mg/ml; Murex Diagnostics) for 3 days and
cultured in Iscove’s medium containing 10% fetal calf serum (PA Biologicals)
and 5% interleukin-2 (Boehringer, Mannheim, Germany). The infectivity of the
viruses derived from cells with altered Gag/Gag-Pol ratios was measured using a
50% tissue culture infective dose (TCID50) method previously described (4).
Two hundred microliters of virus supernatant derived from cells with a predicted
Gag/Gag-Pol ratio of 20:21, 20:11, 20:6, or 20:3.5 was mixed with 105 PBMCs in
a 96-well tissue culture plate. Four 10-fold dilutions of each virus were tested;
each dilution was tested in triplicate. Supernatants were collected on days 3, 7,
FIG. 1. Schematic representation of proviral DNA constructs used
in this study. The wild-type (WT) plasmid is HxB2-BH10 and has been
previously described (43). To obtain the GP PR(1) construct, a PCR-
amplified fragment was cloned into the HxB2-BH10 proviral DNA via
ApaI and BclI restriction sites in order to eliminate the five-T hep-
tanucleotide stretch which is responsible for the 21 ribosomal frame-
shifting during the translation of Gag and allow continuous expression
of Gag-Pol by bypassing the Gag termination codon. The GP PR(2)
plasmid was constructed in the same fashion as GP PR(1), with the
exception that a PR-defective full-length HIV-1 PR(2) plasmid was
used as the DNA template for GP PR(2) PCR mutagenesis (15).
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10, and 14 postinfection and frozen immediately at 270°C. Viral infectivity was
measured by monitoring activity using an RT microassay (13).
Analysis of viral protein within virion-producing cells and virion particles. (i)
Intracellular viral protein analysis. Cell lysates were rapidly freeze-thawed three
times to weaken the cellular membrane. Cell debris was subsequently removed
by centrifugation for 30 min at 4°C and 14,000 rpm (Beckman). The transfection
efficiency of the samples was determined by measuring the level of EGFP from
the reporter plasmid using a Bio Imaging Analyzer (Fuji Photo Film Co.).
Cellular protein from each sample normalized for an equivalent level of EGFP
was mixed with 3 ml of sample buffer (100 mM Tris [pH 6.8], 3% sodium
dodecyl sulfate [SDS], 33% glycerol, 0.03% bromophenol blue), denatured for
10 min in 95°C, and resolved by SDS–10% polyacrylamide gel electrophoresis
(PAGE). Resolved proteins were transferred to a nitrocellulose membrane (Am-
ersham, Amersham, England). The membrane was blocked for 2 h in 3% casein
dissolved in 13 TBS containing 0.3% Tween 20 (TBST) and probed overnight
with pooled HIV-1-seropositive patient sera. After three washes with 13 TBST
buffer, the membrane was incubated with anti-human horseradish peroxidase-
conjugated secondary antibody (DAKO) for 2 h at room temperature. An en-
hanced chemiluminescence technique was used for visualization of HIV-1 pro-
teins present in the cellular lysates (Amersham). Results were visualized by
autoradiography.
(ii) Assessment of Gag/Gag-Pol ratios in virus-producing cells following
transfection. To determine the Gag/Gag-Pol ratios in virus-producing cells, cel-
lular proteins standardized by transfection efficiency were resolved by SDS-
PAGE and probed with monoclonal antibodies to RT and p24 antigen for
detection and quantitation of Pr160gag-pol, p66/51 RT, and p24 CA, respectively.
Data obtained by autoradiography were scanned, and expression levels of these
proteins for each sample were quantified using laser densitometry analysis.
(iii) Virion purification and protein analysis. Supernatants from transfected
cells were purified and concentrated by ultracentrifugation through a 20% su-
crose cushion using a Beckman L-90 ultracentrifuge (SW 41 rotor) at 35,000 rpm
for 1 h at 4°C (29). Pellets were resuspended in 50 ml of TBS lysis buffer.
(iv) Analysis of virion protein profile. Equal amounts of virion protein (nor-
malized by the transfection efficiency of EGFP) from each sample were mixed
with 3 ml of sample buffer containing 5 mM b-mercaptoethanol and heated for
10 min at 95°C. Virion proteins were then resolved by SDS–10% PAGE as
described above. The resolved virion protein samples were transferred onto
nitrocellulose membranes by electrophoresis using a Bio-Rad transfer apparatus.
Virion HIV-1 protein profiles of the samples were determined by Western
analysis as described above.
(v) Quantification of virion protein by dot blot assay. The total virion protein
recovered was standardized by a protein dot blot technique. Briefly, twofold
dilutions of each protein sample were loaded directly onto a nitrocellulose
membrane (Hybond-C extra; Amersham). The membrane was air dried for 30
min at room temperature and blocked for 2 h in 3% casein in 13 TBST. Samples
were probed for total HIV-1 virion protein production as described above.
Results were analyzed either by autoradiography or by phosphorimaging for
quantification of total virion protein.
(vi) Analysis of virion RNA packaging. For virion RNA analysis, HxB2-BH10
proviral DNA was replaced with DRev proviral DNA in a cotransfection. This
was done to ensure that virion particles were produced only when the Gag-Pol-
expressing vector was supplemented in the virus-producing cell, as both Gag
(from the DRev plasmid) and Rev (from either of the Gag-Pol expression
plasmids) are required for successful viral particle production. Pelleted virions
were prepared by ultracentrifugation as described above and resuspended in 500
ml of Trizol (GIBCO) for genomic RNA extraction. Samples were subsequently
incubated for 30 min in ice to allow complete lysis to occur, and 200 ml of
chloroform was added to remove virion proteins. Samples were mixed well and
centrifuged for 5 min at 14,000 rpm and 4°C. The aqueous layer containing the
RNA was transferred to a fresh Eppendorf tube and precipitated with 1/10
volume of 3 M sodium acetate and 1 ml of ice-cold 100% ethanol at 220°C
overnight. Precipitated RNA samples were centrifugated for 30 min at 14,000
rpm (Beckman) and 4°C. The RNA pellets were washed with 200 ml of 70%
ethanol and then air dried for 1 h at room temperature. Each pellet was resus-
pended in 10 ml of RNase-free water and stored at 220°C until use.
The impact of the Gag/Gag-Pol ratio on genomic packaging of virion RNA was
assessed by RNA dot blot assay (39) using a Bio-Rad dot blot apparatus. Serial
10-fold dilutions of virion RNA samples that were normalized by virion protein
were used to construct a standard curve. Each sample was mixed with 29 ml of
RNA denaturation buffer (37% formaldehyde, 60% deionized formamide, 3%
203 SSC [13 SSC is 0.15 M NaCl plus 0.015 M sodium citrate]) and incubated
at 65°C for 10 min for RNA denaturation. After incubation, samples were
immediately chilled in ice. To each tube, 78 ml of 203 SSC buffer was added and
samples were loaded onto a Hybond membrane (Amersham) via a dot blot
apparatus (Bio-Rad). The wells were washed twice with 103 SSC, and the
membrane was air dried overnight at room temperature. The membrane was
exposed to UV light for 90 s to cross-link the RNA onto the membrane and
blocked for 1 h at 42°C with 10 ml of hybridization buffer (40 ml of the hybrid-
ization buffer contains 8 ml of 53 SSPE [13 SSPE is 0.18 M NaCl, 10 mM
NaH2PO4, and 1 mM EDTA at pH 7.7]; 20 ml of deionized formamide, 4 g of
dextran sulfate, 400 ml of salmon sperm DNA [10 mg/ml], 3 ml of 20% sodium
dodecyl sulfate, and 5 ml of double-distilled H2O).
The amount of genomic RNA in viral RNA samples was quantified using a
radioactive antisense oligonucleotide probe, 790H (59CTGACGCTCTCGCAC
CC39), that has been previously described (30). Briefly, the 790H oligomer binds
specifically to HIV-1 genomic RNA sequence positions 338 to 354 (DNA sequ
ence positions 791 to 807). The 790H oligomer was 59 end labeled using T4
polynucleotide kinase and g-32P-labeled ATP (3,000 Ci/mmol; Amersham). The
membrane containing the RNA samples was incubated overnight at 42°C with
the radioactively labeled probe. The membrane was washed once for 30 min with
13 SSC–0.1% SDS and twice with 0.23 SSC–0.13 SDS for 30 min. The results
were visualized by autoradiography. The amount of genomic RNA packaged by
wild-type virions was used as a control to determine the impact of the Gag/Ga
g-Pol ratio on virion RNA packaging.
Virion RNAs that were normalized by virion protein concentration were also
analyzed by Northern blot assay using three serial 10-fold dilutions to determine
the stability of the 9-kb unspliced genomic RNA. Samples were mixed with 10%
53 formaldehyde running buffer, 17.5% formaldehyde, and 50% formamide and
incubated for 15 min at 65°C and then quickly chilled in ice for 15 min. A 2-ml
sample of sterile formaldehyde gel loading buffer (50% glycerol, 1 mM EDTA,
0.25% bromophenol blue, 0.25% xylene cyanol FF) was added to each tube, and
virion RNAs were separated on a 1% denaturing agarose gel. RNA samples were
transferred onto a Hybond membrane, UV cross-linked, and probed for 9-kb
HIV-1 genomic RNA using an HIV-specific PCR radioactive probe as previously
described (14). Results were visualized by autoradiography.
(vii) Analysis of virion RNA dimerization. Virion pellets were resuspended in
500 ml of dimerization buffer (10 mM Tris [pH 7.5], 1 mM EDTA, 1% SDS, 50
mM NaCl, yeast tRNA at 50 mg/ml, proteinase K at 100 mg/ml), phenol-chloro-
form extracted, and isolated for melting curve analysis as previously described
(11, 12).
Similar amounts of genomic RNA were used to analyze the stability of the
virion RNA dimer in each preparation by heating the samples at the indicated
temperatures for 10 min and then quickly chilling them in ice. Heat-denatured
dimeric and monomeric RNAs were separated by electrophoresis in a 1% native
agarose gel in 0.53 Tris-borate-EDTA buffer. Samples were transferred over-
night onto a Hybond N membrane (Amersham). The membrane containing the
RNA samples was air dried for 2 h at room temperature and exposed to UV light
for 90 s for cross-linking. The membrane was blocked for 1 h at 42°C with 10 ml
of hybridization buffer as described above.
Dimeric and monomeric RNAs were subjected to an overnight incubation with
a radioactive riboprobe (pGEM7zHIV-1) which is complementary to the 59 end
of the HIV-1 genomic RNA sequences. Briefly, a 1,390-bp HindIII-SphI HIV-1
DNA fragment was cloned into an in vitro transcription vector, pGEM7z, via
restriction sites HindIII and SphI. An 800-bp DNA fragment corresponding to
the Gag-encoding region was subsequently removed by PstI and BssHII restric-
tion digestion and S1 nuclease treatment, followed by self-religation to generate
pGEM7z HIV-1. The removal of the 800-bp Gag coding region shortens the
length of the in vitro HIV-1 RNA transcript and reduces the nonspecific binding
of the riboprobe. The radioactive riboprobe was synthesized by linearization of
pGEM7z HIV-1 with BamHI, followed by T7 RNA polymerase-directed in vitro
transcription (Promega) in the presence of [a-32P]CTP (NEN). After probing,
the membrane was washed once for 30 min with 13 SSC–0.1% SDS buffer and
twice for 30 min (each time) with 0.23 SSC–0.1% SDS buffer, and the results
were visualized by autoradiography. Migration of wild-type mature and PR-
defective immature dimeric and monomeric RNA at the respective heating
temperatures was used as a control to determine the effect of the Gag/Gag-Pol
ratio on RNA dimerization for viruses derived from cells with altered ratios.
RESULTS
Effects of altered Gag/Gag-Pol ratios on HIV-1 protein pro-
files in virus-producing cells. 293T cells were transfected with
wild-type DNA (HxB2-BH10; producing a 20:1 Gag/Gag-Pol
ratio as a control) or cotransfected with either a Gag-Pol ex-
pression vector encoding an active PR site, GP PR(1), or a
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PR-defective Gag-Pol expression vector, GP PR(2), to pro-
gressively alter this ratio from 20:1 to 20:21. Following trans-
fection, cells were lysed and expression of EGFP was quanti-
fied to standardize transfection efficiency for each sample (data
not shown). Cellular proteins from samples normalized for
transfection efficiency were resolved by SDS–10% PAGE and
probed with human HIV antisera. Compared with wild-type
DNA alone (Fig. 2A, lane 1), cotransfection with the GP
PR(1) plasmid increased intracellular levels of Gag-Pol prod-
ucts, e.g., p66 RT and p51 RT (Fig. 2A, lanes 2 to 5). In
contrast, cotransfection of the GP PR(2) plasmid resulted in
higher levels of precursor Pr160 Gag-Pol and reduced levels of
Gag-Pol products (e.g., p24-CA) (Fig. 2A, lanes 6 to 9). Inter-
mediate Gag-Pol processing products corresponding to p98
RT-IN, p110 PR-RT-IN, and p119 p2-p7-PR-RT-IN were also
detected when either GP PR(1) or GP PR(2) was cotrans-
fected. The wild-type HIV-1 pattern was gradually restored as
the ratio approached 20:1.
Quantification of Gag/Gag-Pol ratios of mutant viruses in
virus-producing cells. As assessed by laser densitometry, the
expression of the p66/51 RT in virus-producing cell correlated
with the input levels of GP PR(1) used during transfection. An
approximately twofold increase in RT protein was detected
for every subsequent twofold increase in GP PR(1) plasmid
DNA used, with the p66/RT densitometry units being 150,000,
87,000, 35,000, and 15,000 (Fig. 2A, lanes 2, 3, 4, and 5, re-
spectively). A similar, Gag/Gag-Pol ratio-dependent, p24 CA
level was also detected when an anti-p24 monoclonal antibody
was used (Fig. 2A, lanes 2 to 5). Densitometry units of p24 CA
expression were 268,000, 160,000, 50,320, and 25,770, respec-
tively. No detectable difference in p66/51 RT was observed in
cells transfected with an excess of GP PR(2) compared to the
wild-type control, while intracellular p24 CA expression levels
showed reduction in a dose-responsive manner (Fig. 2A, lanes
6 to 9). The intensity of intracellular p24 CA signals was in-
versely proportional to the detectable levels of Pr160gag-pol
(Fig. 2A, lanes 6 to 9).
Effects of altered Gag/Gag-Pol ratios on virion protein pat-
terns. Purified viral particles derived from cotransfected cells
(as described above) were analyzed by Western blot assay.
Virions derived from cells overexpressing GP PR(1) showed
slightly low levels of Pr160gag-pol, p66 RT, and p24 CA but
otherwise maintained virion protein profiles similar to those of
wild-type virions (Fig. 2B, lanes 1 and 2). The virion proteins
returned toward wild-type levels as the Gag/Gag-Pol ratio ap-
proached 20:1 (Fig. 2B, lanes 1 to 5). Cells with a Gag/Gag-Pol
ratio of 20:21 produced 10 times less supernatant p24 than cells
producing only wild-type virus (Table 1). Overexpression of
GP PR(2), however, altered both the levels and profiles of
virion proteins in a ratio-dependent fashion (Fig. 2B, lanes 6,
7, 8, and 9). Notably, the p66 RT band disappeared and only
low levels of p24 CA were detected when the Gag/Gag-Pol
ratio was altered from 20:1 to 20:21 (Fig. 2B, lanes 1 and 6).
The levels of mature and intermediate virion proteins, e.g., p66
RT, p51 RT, p24 CA, and p39 MA-CA, were inversely related
to the presence of Pr55gag (Fig. 2B, lanes 6 to 9).
FIG. 2. Impact of altered Gag/Gag-Pol ratios on HIV-1 protein
profiles of infected cells and virions. Viral proteins were semiquanti-
fied by Western blot analysis. Cell lysates (A) and purified virions (see
Materials and Methods) (B) were resolved by SDS–10% PAGE. Re-
solved proteins were probed using sera from HIV-1-infected individ-
uals and monoclonal antibodies (Ab) to RT and p24 as described in
Materials and Methods. Lane 1 (A and B) shows wild-type (WT)
HIV-1 protein profiles in cell lysates and virions, respectively; lanes 2
to 5 (A and B) show cell lysate and virion protein profiles with esti-
mated HIV-1 Gag/Gag-Pol ratios of 20:21, 20:11, 20:6, and 20:3.5,
respectively. A GP PR(1) expression vector was used to produce
excessive levels of Gag-Pol in lanes 2 to 5 (see Materials and Methods).
Similarly, lanes 6 to 9 show cell lysate and virion protein profiles with
estimated HIV-1 Gag/Gag-Pol ratios of 20:21, 20:11, 20:6, and 20:3.5,
respectively. Expression vector GP PR(2) was used to produce an
excess of Gag-Pol protein that is not processed by PR in lanes 6 to 9
(see Materials and Methods). MA, matrix.
TABLE 1. Production of HIV-1 particles from cells with
altered Gag/Gag-Pol ratios
Proviral DNAs used in
cotransfections
(quantities [-/mg])
Predicted Gag/
Gag-Pol ratio in virus-
producing cells
Level of virion
production
(ng of p24/ml)a
WT (10) 20:1 1,176
WT, GP PR(1) (10, 10) 20:21 99
WT, GP PR(1) (10, 5) 20:11 111
WT, GP PR(1) (10, 2.5) 20:6 189
WT, GP PR(1) (10, 1.25) 20:3.5 713
WT, GP PR(2) (10, 10) 20:21 90
WT, GP PR(2) (10, 5) 20:11 120
WT, GP PR(2) (10, 2.5) 20:6 207
WT, GP PR(2) (10, 1.25) 20:3.5 386
a The levels of virion production (as determined by quantitative p24 assay)
from a set of representative experiments are included.
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Assessment of the effect of an altered Gag/Gag-Pol ratio on
virus infectivity. Wild-type or mutant virus suspensions derived
from harvested cells were assayed for infectivity, RT activity,
and p24 antigen concentration. End point dilution infectivity
assay results (TCID50) were normalized to RT or p24. Progeny
viruses derived from cells with a Gag/Gag-Pol ratio of 20:21
were 250 to 1,000 times less infectious than the wild-type virus
(Fig. 3 and Table 2). Similar decreases in infectivity, in a clearly
ratio-dependent fashion, were seen in virions derived from
cells with excess GP PR(1) or GP PR(2).
Relationship of intracellular Gag/Gag-Pol ratio, virion
RNA packaging, and RNA dimerization. To investigate the
impact of the Gag/Gag-Pol ratio on RNA dimerization and
dimer stability, virus suspensions obtained using the transfec-
tion methods described above were studied. Similar amounts
of virion RNA were treated at different temperatures, and
dimeric and monomeric virion RNAs were resolved by elec-
trophoresis (Fig. 4). Dimeric RNA was observed in all viruses
derived from cells in which GP PR(1) was overexpressed.
These RNA dimers were only slightly less stable than wild-type
dimers (Fig. 4A, compare the wild-type ratio with 20:21 at 45,
48, and 50°C), and the degree of instability correlated with the
level of excess PR(1) Gag-Pol proteins in virion-producing
cells (Fig. 4A). In contrast to the results obtained with GP
PR(1), supplementing virus-producing cells with a PR-inac-
tive Gag-Pol expression vector [GP PR(2)] markedly reduced
RNA dimerization in a concentration-dependent fashion (Fig.
4B). When the Gag/Gag-Pol ratio of the virion-producing cells
was altered from 20:1 to 20:21 with the GP PR(2) protein
FIG. 3. Infectivity of viral particles produced by cells with a wild-
type or altered Gag/Gag-Pol ratio. Freshly isolated PBMCs were phy-
tohemagglutinin stimulated for 3 days and then infected with either
wild-type or mutant virus. Supernatants were collected 3, 7, 10, and 14
days (d) after infection, and the RT activity in each sample was mea-
sured. The results shown represent the mean and standard deviation of
triplicate samples. Open symbols represent viruses derived from cells
with an excess of PR(1) Gag-Pol, and closed symbols (except aster-
isks) represent viruses derived from cells with excess of PR(2) Gag-
Pol. Symbols: p, wild-type virus; } and {, progeny viruses of cells with
a predicted 20:3.5 Gag/Gag-Pol ratio;  and , predicted 20:6 Gag/
Gag-Pol ratio; n and h, predicted 20:11 Gag/Gag-Pol ratio; F and E,
predicted 20:21 Gag/Gag-Pol ratio.
TABLE 2. Infectivity of virus particles derived from cells with
altered Gag/Gag-Pol ratiosa
Proviral
DNA(s) used
Gag/Gag-Pol
ratio in virus-
producing
cells
Gag and Gag-
Pol processing
phenotyped
Virion infectivity
(TCID50)a
standardized for:
RT activityb p24 levelc
WT 20:1 1111 1,300.0 480.0
WT, GP PR(1) 20:21 1111 1.4 5.6
WT, GP PR(1) 20:11 1111 1.5 5.0
WT, GP PR(1) 20:6 1111 13.0 17.0
WT, GP PR(1) 20:3.5 1111 130.0 79.0
WT, GP PR(2) 20:21 6 5.2 3.5
WT, GP PR(2) 20:11 1 5.0 4.7
WT, GP PR(2) 20:6 11 28.0 27.0
WT, GP PR(2) 20:3.5 111 150.0 140.0
a TCID50 was measured as described in Materials and Methods.
b The values shown are TCID50s (1024) per count per minute of RT activity.
c The values shown are TCID50s (1021) per nanogram of p24 antigen.
d 1111, very strong; 111, strong; 11, medium; 1, weak; 6, very weak.
FIG. 4. Effect of altered Gag/Gag-Pol ratios on virion RNA dimer-
ization. The impact of various Gag/Gag-Pol ratios on genomic RNA
dimerization was determined using melting curve and electrophoretic
analysis of wild-type (WT) and mutant dimers. Virion RNA was re-
suspended in RNA dimerization buffer and heat denatured for 10 min
at the indicated temperatures. Dimers and monomers were electro-
phoresed in a 1% native agarose gel and probed with an HIV-1 ribo-
probe as described in Materials and Methods. RNA dimerization anal-
ysis involved wild-type HIV-1 and mutant viruses derived from cells
cotransfected with wild-type and GP PR(1) expression vectors to
achieve Gag/Gag-Pol ratios of 20:1 to 20:21 (A), cells cotransfected
with wild-type and GP PR(2) expression vectors to achieve Gag/Gag-
Pol ratios of 20:3.5 to 20:21 (B), and cells transfected with wild-type
proviral DNA, transfected with a PR-defective full-length HIV-1 Pr-
defective plasmid [PR(2)] for the production of PR-defective imma-
ture HIV-1 particles, and cotransfected with wild-type GP PR(2) to
achieve a Gag/Gag-Pol ratio of 20:21 (C). U, unheated.
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expression vector, progeny virions contained mainly mono-
meric RNA (Fig. 4B). The few RNA dimers in these aberrant
viral particles dissociated at temperatures 15 to 20°C lower
than the dimeric RNA found in PR-defective immature and
wild-type mature HIV-1 virions, respectively (Fig. 4C).
Recent work on Rous sarcoma virus (RSV) has shown that
a 50% reduction in virion RNA packaging in a mutant RSV is
associated with a defect in virion RNA dimer formation (35).
To rule out this possibility, the level of packaged genomic
RNA in our monomeric RNA virions was compared with wild-
type HIV-1 and PR-defective immature HIV-1 virions [via
transfection of PR(2) alone]. Wild-type and mutant viruses
were examined by RNA dot blot assay to assess the influence
of the Gag/Gag-Pol ratio on RNA packaging (Fig. 5B), and the
stability of the full-length genomic RNA was analyzed by
Northern blotting (Fig. 5C). Equivalent amounts of genomic
RNA packaging were found in wild-type HIV-1 (Fig. 5B, row
1), PR-defective immature HIV-1 virions (Fig. 5B, row 3), and
the monomeric RNA virions (Fig. 5B, row 4) when normalized
for HIV-1 protein concentration. Transfection of GP PR(2)
alone into 293T cells results in expression of the Gag-Pol
precursor protein. Expression of the Gag-Pol precursor pro-
tein without Gag yielded low but detectable levels of HIV-1
proteins (8- to 10-fold lower than those seen following wild-
type plasmid transfection as determined by Fuji FLA 2000
phosphorimaging) (Fig. 5A, row 2) but negligible levels of
virion genomic RNA (at least 100-fold lower than the wild
type) when normalized for HIV-1 protein concentration (Fig.
5B, row 2) compared to that from the wild-type virus (Fig. 5B,
row 1). These results show that the monomeric RNA packaged
into virions was not contaminated with pelletable Gag-Pol pre-
cursor protein. Similar levels of genomic RNA packaging were
found in all of the other viruses tested, and the level of the viral
RNA packaged was not affected by the stability of RNA dimers
or the nature of the Gag-Pol expression vector [i.e., GP PR(1)
or GP PR (2)] (data not shown).
Northern analysis of the packaged genomic RNA showed
that the 9-kb genomic RNA derived from our monomeric
RNA virions was intact in comparison to the wild-type mature
and PR-defective immature HIV-1 (Fig. 5C). Alteration of the
Gag/Gag-Pol ratio neither affected RNA packaging nor pro-
moted degradation of the 9-kb genomic RNA.
DISCUSSION
Using a cotransfection system, we have demonstrated that
alteration of the Gag/Gag-Pol ratio in virus-producing cells
reduces the infectivity of progeny viruses and hinders the for-
mation of stable virion RNA dimers without impairing virion
packaging of genomic RNA. This study shows for the first time
that maintenance of the normal Gag/Gag-Pol ratio is impor-
tant for HIV-1 replication. Although both the proteolytic pro-
cessing of HIV-1 proteins and a normal intracellular Gag/Gag-
Pol ratio are required for RNA dimerization, the formation of
stable RNA dimers is not essential for the packaging of HIV-1
genomic RNA.
The identification of translational suppression in retrovi-
ruses has provided crucial information regarding retroviral
gene expression. With the exception of foamy viruses, the ex-
pression of pol gene products in all retroviruses requires trans-
lational suppression (28) to maintain a Gag/Gag-Pol expres-
sion ratio of 20:1 in virion-producing cells. The evolutionary
conservation of the Gag/Gag-Pol ratio in retroviruses supports
its importance in the retroviral replication cycle (17–20, 34). In
our study, we have examined the relevance of this ratio by
altering the Gag/Gag-Pol ratio in the virus-producing cell via
supplementing Gag-Pol expression vectors in HIV-1-trans-
fected cells.
Gag/Gag-Pol ratio and viral protein expression. The impact
of overexpression of PR(1) Gag-Pol was reflected in intracel-
lular viral protein concentrations. The reduction in intracellu-
lar mature Gag and Gag-Pol products in cells containing an
excess of PR(2) Gag-Pol is considered to be due to the trans-
dominant negative effect of PR-defective Gag-Pol proteins (1,
33). The reduction of viral particle production in cells contain-
ing excess GP PR(1) can, in part, be explained by overexpres-
sion of viral PR. Intracellular overexpression of HIV-1 PR
inhibits HIV-1 replication (21), while overexpression of intra-
cellular Gag-Pol precursor proteins interferes with HIV-1 as-
sembly (22, 37). The reduced levels of p24 and RT in the
supernatant of cells containing excess GP PR(2) is possibly
due to inactivation of the viral PR function, as our p24 immu-
noassay used for p24 antigen detection does not recognize
Pr55gag as efficiently as p24 CA. Therefore, it is also likely that
we have underestimated the number of viral particles being
FIG. 5. Effect of altered Gag/Gag-Pol ratios on packaging of genomic RNA. Three types of HIV-1 virions were used in this analysis; they were
wild-type HIV-1 (WT), Pr-defective immature HIV-1 [PR(2)], and virions containing mainly monomeric RNA [WT:GP PR(2) (20:21)].
Supernatant collected from cells expressing only Gag-Pol precursor protein was also used as a control. Quantitation of pelleted viral protein was
performed by protein dot immunoblot assay (A). Samples for RNA analysis (B and C) were standardized for protein concentration (A). Virion
RNA encapsidation efficiency of wild-type and mutant viruses was analyzed by RNA dot blot hybridization assay (B). A series of 10-fold dilutions
was done for quantitation. The stability of the virion-packaged RNA genome was determined by Northern blot analysis (see Materials and Methods
for details of procedures) (C).
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produced from cells overexpressing PR-defective Gag-Pol,
hence overestimating the infectivity of the mutant viral parti-
cles produced via overexpression of PR(2) Gag-Pol.
Gag/Gag-Pol ratio, virion RNA packaging, and dimeriza-
tion. Our data show that alteration of the Gag/Gag-Pol ratio
did not influence HIV-1 RNA packaging. In contrast, expres-
sion of Gag-Pol precursor protein alone yielded eightfold less
virion protein than that found in the wild type and packaged
negligible levels (100 times less than the wild type) of genomic
RNA for equivalent amounts of virion proteins. The latter
observation is in agreement with the study of Kaye and Lever,
which showed that expression of Gag-Pol protein alone yields
pelletable virion proteins that do not encapsidate virion RNA
(25). Others have also reported that expression of Gag-Pol
protein alone is insufficient for the production of virus-like
particles (36, 41) and that the formation of viral particles
requires the expression of Gag precursor proteins (for a re-
view, see reference 45). We have previously shown that expres-
sion of HIV-1 Gag-Pol [either GP PR(1) or GP PR(2)] is
important for the virion packaging of primer tRNALys3 in
HIV-1 (29) and that overexpression of primer tRNALys3 en-
hances virion packaging of primer tRNA (16). Using a con-
verse approach, our experiments also suggest that overexpres-
sion of Gag-Pol does not affect the virion packaging of primer
tRNALys3 (M. Shehu-Xhilaga et al., unpublished data).
These studies show that overexpression of PR(1) Gag-Pol
protein has a minor effect on virion RNA dimerization and
that this impairment of virion RNA dimerization can be am-
plified via overexpression of a trans-dominant PR-negative
Gag-Pol expression vector. Fu et al. (11, 12) have shown that
proteolytic processing of retroviral precursor proteins is im-
portant for the maturation of virion RNA dimers to a more
heat-stable form. In addition to the importance of precursor
protein processing in virion RNA dimer maturation, we have
found that a Gag-Gag-Pol ratio reduction also yields viral
particles with unstable (highly heat-sensitive) RNA dimers, a
defect which is clearly not due to the inactivation of the viral
PR alone.
Furthermore, our experiments provide direct evidence that
the formation of stable virion RNA dimers is not required for
virion RNA packaging. Previous work has shown that in ret-
roviruses, genomic RNA packaging and virion RNA dimeriza-
tion are closely linked (for a review, see reference 3). A recent
publication by Parent et al. (35) showed that a mutation in the
RS matrix sequence interfered with the formation of RNA
dimers and reduced virion RNA packaging by 50%. With our
work, we were able to produce viral particles containing mainly
monomeric RNA merely by increasing the concentration of
PR(2) Gag-Pol in HIV-1-producing cells. This was achieved
without introducing mutations into the HIV-1 RNA packaging
region or the 59 end of the Gag coding sequences.
HIV-1 virions produced from cells containing altered Gag/
Gag-Pol ratios showed dramatically reduced infectivity (Table
2). The mechanism of this effect is unclear, as virions derived
from cells with a Gag/Gag-Pol ratio of 20:21 [due to an excess
of GP PR(1)] had protein profiles and levels of virion-encap-
sidated RNA equivalent to those of wild-type HIV-1, despite
having ;1,000-fold decreased infectivity. As the mRNAs for
both GP PR(1) and GP PR(2) contain wild-type RNA pack-
aging sequences, it is conceivable that the packaging of GP
PR(1) or GP PR(2) mRNA can, in part, contribute to the
reduction in viral infectivity observed here. The highest intra-
cellular level of GP PR(1) or GP PR(2), however, has never
exceeded the mRNA levels of wild-type HxB2-BH10 (Table 1).
If the viral infectivity of the progeny viruses with altered Gag/
Gag-Pol ratios is a function of the encapsidated genome, a
maximum twofold reduction in viral infectivity would be an-
ticipated. Clearly, the maintenance of virion infectivity is at
least one explanation for the conserved Gag/Gag-Pol ratio of
20:1 in all retroviruses. The maintenance of this evolutionarily
conserved Gag/Gag-Pol ratio in retroviruses may represent a
previously unexplored mechanism for regulation of retrovi-
ral assembly, and ultrastructural study of retroviral particles
produced in cells with altered Gag/Gag-Pol ratios may provide
further insight into the functional importance of this ratio in
the retroviral replication cycle.
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